This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Armour, K. E. Articles by Ralston, S. H. Search for Related Content PubMed PubMed Citation Articles by Armour, K. E. Articles by Ralston, S. H.

Defective Bone Formation and Anabolic Response to Exogenous Estrogen in Mice with Targeted Disruption of Endothelial Nitric Oxide Synthase¹

Department of Medicine and Therapeutics, Foresterhill, University of Aberdeen Medical School, Aberdeen, AB25 2ZD, United Kingdom; and Institüt für Herz- und Kreislaufphysiologie (A.G.), Heinrich-Heine-Universität, 40225 Düsseldorf, Germany

Address all correspondence and requests for reprints to: Professor S. H. Ralston, Department of Medicine and Therapeutics, University of Aberdeen Medical School, Foresterhill, Aberdeen, AB25 2ZD, United Kingdom. E-mail: s.ralston{at}aberdeen.ac.uk

Nitric oxide (NO) is a pleiotropic signaling molecule that is produced by bone cells constitutively and in response to diverse stimuli such as proinflammatory cytokines, mechanical strain, and sex hormones. Endothelial nitric oxide synthase (eNOS) is the predominant NOS isoform expressed in bone, but its physiological role in regulating bone metabolism remains unclear. Here we studied various aspects of bone metabolism in female mice with targeted disruption of the eNOS gene. Mice with eNOS deficiency (eNOS KO) had reduced bone mineral density, and cortical thinning when compared with WT controls and histomorphometric analysis of bone revealed profound abnormalities of bone formation, with reduced osteoblast numbers, surfaces and mineral apposition rate. Studies in vitro showed that osteoblasts derived from eNOS KO mice had reduced rates of growth when compared with WT and were less well differentiated as reflected by lower levels of alkaline phosphatase activity. Mice with eNOS deficiency lost bone normally following ovariectomy but exhibited a significantly blunted anabolic response to high dose exogenous estrogen. We conclude that the eNOS pathway plays an essential role in regulating bone mass and bone turnover by modulating osteoblast function.

This article has been cited by other articles:

				S. J. Wimalawansa, J. P. Grimes, A. C. Wilson, and D. R. Hoover Transdermal Nitroglycerin Therapy May Not Prevent Early Postmenopausal Bone Loss J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3356 - 3364. [Abstract] [Full Text] [PDF]

				H. Rangaswami, N. Marathe, S. Zhuang, Y. Chen, J.-C. Yeh, J. A. Frangos, G. R. Boss, and R. B. Pilz Type II cGMP-dependent Protein Kinase Mediates Osteoblast Mechanotransduction J. Biol. Chem., May 29, 2009; 284(22): 14796 - 14808. [Abstract] [Full Text] [PDF]

				F. A. Gerhard, D. J. Webster, G. H. van Lenthe, and R. Muller In silico biology of bone modelling and remodelling: adaptation Phil Trans R Soc A, May 28, 2009; 367(1895): 2011 - 2030. [Abstract] [Full Text] [PDF]

				A. I. Idris, I. R. Greig, E. Bassonga-Landao, S. H. Ralston, and R. J. van 't Hof Identification of Novel Biphenyl Carboxylic Acid Derivatives as Novel Antiresorptive Agents that Do Not Impair Parathyroid Hormone-Induced Bone Formation Endocrinology, January 1, 2009; 150(1): 5 - 13. [Abstract] [Full Text] [PDF]

				I. Kanazawa, T. Yamaguchi, S. Yano, M. Yamauchi, and T. Sugimoto Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression Am J Physiol Endocrinol Metab, January 1, 2009; 296(1): E139 - E146. [Abstract] [Full Text] [PDF]

				A. I. Idris, A. Sophocleous, E. Landao-Bassonga, R. J. van't Hof, and S. H. Ralston Regulation of Bone Mass, Osteoclast Function, and Ovariectomy-Induced Bone Loss by the Type 2 Cannabinoid Receptor Endocrinology, November 1, 2008; 149(11): 5619 - 5626. [Abstract] [Full Text] [PDF]

				S. Yano, T. Yamaguchi, I. Kanazawa, N. Ogawa, K. Hayashi, M. Yamauchi, and T. Sugimoto The uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure Nephrol. Dial. Transplant., November 1, 2007; 22(11): 3160 - 3165. [Abstract] [Full Text] [PDF]

				Z. Liu, Y. Jiang, H. Hao, K. Gupta, J. Xu, L. Chu, E. McFalls, J. Zweier, C. Verfaillie, and R. J. Bache Endothelial nitric oxide synthase is dynamically expressed during bone marrow stem cell differentiation into endothelial cells Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1760 - H1765. [Abstract] [Full Text] [PDF]

				B. B. Yaroslavskiy, A. C. Sharrow, A. Wells, L. J. Robinson, and H. C. Blair Necessity of inositol (1,4,5)-trisphosphate receptor 1 and {micro}-calpain in NO-induced osteoclast motility J. Cell Sci., August 15, 2007; 120(16): 2884 - 2894. [Abstract] [Full Text] [PDF]

				A. M. From, J. A. Hyder, A. E. Kearns, K. R. Bailey, and P. A. Pellikka Relationship Between Low Bone Mineral Density and Exercise-Induced Myocardial Ischemia Mayo Clin. Proc., June 1, 2007; 82(6): 679 - 685. [Abstract] [Full Text] [PDF]

				J. F. Griffith, D. K. W. Yeung, G. E. Antonio, S. Y. S. Wong, T. C. Y. Kwok, J. Woo, and P. C. Leung Vertebral Marrow Fat Content and Diffusion and Perfusion Indexes in Women with Varying Bone Density: MR Evaluation Radiology, December 1, 2006; 241(3): 831 - 838. [Abstract] [Full Text] [PDF]

				F. Grassi, X. Fan, J. Rahnert, M. N. Weitzmann, R. Pacifici, M. S. Nanes, and J. Rubin Bone Re/Modeling Is More Dynamic in the Endothelial Nitric Oxide Synthase(-/-) Mouse Endocrinology, September 1, 2006; 147(9): 4392 - 4399. [Abstract] [Full Text] [PDF]

				C. Zaragoza, E. Lopez-Rivera, C. Garcia-Rama, M. Saura, A. Martinez-Ruiz, T. R. Lizarbe, F. Martin-de-Lara, and S. Lamas Cbfa-1 mediates nitric oxide regulation of MMP-13 in osteoblasts. J. Cell Sci., May 1, 2006; 119(Pt 9): 1896 - 1902. [Abstract] [Full Text] [PDF]

				B. B. Yaroslavskiy, Y. Zhang, S. E. Kalla, V. G. Palacios, A. C. Sharrow, Y. Li, M. Zaidi, C. Wu, and H. C. Blair NO-dependent osteoclast motility: reliance on cGMP-dependent protein kinase I and VASP J. Cell Sci., December 1, 2005; 118(23): 5479 - 5487. [Abstract] [Full Text] [PDF]

				X. Zhao, S. Zhuang, Y. Chen, G. R. Boss, and R. B. Pilz Cyclic GMP-dependent Protein Kinase Regulates CCAAT Enhancer-binding Protein {beta} Functions through Inhibition of Glycogen Synthase Kinase-3 J. Biol. Chem., September 23, 2005; 280(38): 32683 - 32692. [Abstract] [Full Text] [PDF]

				D. Hamerman Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies QJM, July 1, 2005; 98(7): 467 - 484. [Abstract] [Full Text] [PDF]

				E. Bonnelye and J. E. Aubin Estrogen Receptor-Related Receptor {alpha}: A Mediator of Estrogen Response in Bone J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3115 - 3121. [Abstract] [Full Text] [PDF]

				R. J. van't Hof, J. MacPhee, H. Libouban, M. H. Helfrich, and S. H. Ralston Regulation of Bone Mass and Bone Turnover by Neuronal Nitric Oxide Synthase Endocrinology, November 1, 2004; 145(11): 5068 - 5074. [Abstract] [Full Text] [PDF]

				T. M. Doherty, L. A. Fitzpatrick, D. Inoue, J.-H. Qiao, M. C. Fishbein, R. C. Detrano, P. K. Shah, and T. B. Rajavashisth Molecular, Endocrine, and Genetic Mechanisms of Arterial Calcification Endocr. Rev., August 1, 2004; 25(4): 629 - 672. [Abstract] [Full Text] [PDF]

				X. Fan, E. Roy, L. Zhu, T. C. Murphy, C. Ackert-Bicknell, C. M. Hart, C. Rosen, M. S. Nanes, and J. Rubin Nitric Oxide Regulates Receptor Activator of Nuclear Factor-{kappa}B Ligand and Osteoprotegerin Expression in Bone Marrow Stromal Cells Endocrinology, February 1, 2004; 145(2): 751 - 759. [Abstract] [Full Text] [PDF]

				J. Rubin, T. C. Murphy, L. Zhu, E. Roy, M. S. Nanes, and X. Fan Mechanical Strain Differentially Regulates Endothelial Nitric-oxide Synthase and Receptor Activator of Nuclear {kappa}B Ligand Expression via ERK1/2 MAPK J. Biol. Chem., September 5, 2003; 278(36): 34018 - 34025. [Abstract] [Full Text] [PDF]

				T. Abe, H. Hikiji, W. S. Shin, N. Koshikiya, S.-i. Shima, J. Nakata, T. Susami, T. Takato, and T. Toyo-oka Targeting of iNOS with antisense DNA plasmid reduces cytokine-induced inhibition of osteoblastic activity Am J Physiol Endocrinol Metab, September 1, 2003; 285(3): E614 - E621. [Abstract] [Full Text] [PDF]